Fig. 1From: Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancerCONSORT diagram of the Stockholm HER2 cohort. ASCO American Society of Clinical Oncology, BC breast cancer, CAP College of American Pathologists, CNB core needle biopsy, DCIS ductal cancer in situ, ISH in situ hybridization, RFS recurrence-free survivalBack to article page